Alzheimer’s is a progressive mental deterioration that can occur in middle or old age, due to generalized degeneration of the brain. It is the most common cause of premature senility. Biotechnology firms like Biogen Idec (NASDAQ:BIIB) are still looking for breakthrough cures and treatments for this fatal disease but feel that have the right experimental drug to treat Alzheimer disease. Recent results have shown the experimental drug BIIB037 slowed patients’’ inexorable cognitive decline.
The results may have lead drug companies to revamp their strategy. Treat the patient early, when the disease is in its early stages and use brain imaging to ensure that each patient already possesses the amyloid plaques that help cause the disease. According to a review in a recent press release, the data shows that Biogen might be on to something. The only issue that has risen is doctors are a little skeptical because of the small size study, and it leaves some doubt about whether BIIB037 will work in larger studies where common drugs have failed.
According to Samuel Gandy, who works for the Mount Sinai School of Medicine as an Alzheimer’s researcher states, “The data are convincingly encouraging.” Grandy who is very critical about drugs like BIIB037 says, “I’m willing to suspend disbelief.” Now if Biogen’s medicine does prove to work where others’ have not, the reason is because the company has a better medicine, or the company just picked the right patients for it’s research. Although odds are against BIIB it would be nice to see a treatment breakthrough for this horrific disease killing many every year.